Advertisement

Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer

  • Nicole C. LoronaEmail author
  • Linda S. Cook
  • Mei-Tzu C. Tang
  • Deirdre A. Hill
  • Charles L. Wiggins
  • Christopher I. Li
Article
  • 54 Downloads

Abstract

Oral contraceptive use is a well-established risk factor for breast cancer and is common among reproductive-aged women in the USA. Its relationship with less common, more aggressive, molecular subtypes is less clear. A population-based case-case analysis was conducted comparing three less common molecular subtypes to luminal A breast cancer among 1701 premenopausal cases aged 21–49 diagnosed with a first primary invasive breast cancer between 2004 and 2015. Medical record reviews and structured interviewer-administered questionnaires were used to collect data on oral contraceptive use. Multinomial logistic regression was used to estimate odds ratios (OR) and corresponding 95% confidence intervals (95% CI) for recency of oral contraceptive use for each subtype of breast cancer. Current use of oral contraceptives and use within 5 years before diagnosis was associated with lower odds of H2E tumors compared with luminal A tumors [OR = 0.5, 95% CI: 0.3, 0.9 and OR = 0.5, 95% CI: 0.4, 0.8, respectively] with increasing duration associated with decreasing odds (p for trend < 0.05). Oral contraceptive use was not associated with risks of TN or luminal B breast cancer. Oral contraceptive use may be more strongly positively associated with risks of luminal A, luminal B, and TN breast cancer than with risk of H2E tumors. These findings contribute to the etiological understanding of different molecular subtypes of breast cancer.

Keywords

Oral contraceptives Breast cancer Triple-negative HER2-overexpressing Luminal 

Notes

Funding

This project was supported by the National Cancer Institute (grant numbers: 261201000029C (to C.I. Li), P50 CA148143 (to L.S. Cook, D.A. Hill, C.I. Li), 261201000033C (to C.L. Wiggins), Cancer Center Support Grant 2 P30 CA118100-11 (to L.S. Cook, D.A. Hill, C.L. Wiggins), and Contract HHSN261201800014I, Task Order HHSN26100001 (to C.L. Wiggins)) and the Department of Defense Breast Cancer Research Program (grant number: BC112721 (to C.I. Li)).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713–1727CrossRefGoogle Scholar
  2. 2.
    Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MWR, Provenzano E, Dawson S-J, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279.  https://doi.org/10.1371/journal.pmed.1000279 CrossRefGoogle Scholar
  3. 3.
    Beaber EF, Malone KE, Tang M-TC, Barlow WE, Porter PL, Daling JR, Li CI (2014) Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomark Prev 23:755–764.  https://doi.org/10.1158/1055-9965.EPI-13-0944 CrossRefGoogle Scholar
  4. 4.
    Bethea TN, Rosenburg L, Hong C-C, Rosenberg L, Hong C-C, Troester MA, Lunetta KL, Bandera EV, Schedin P, Kolonel LN, Olshan AF, Ambrosone CB, Palmer JR (2015) A case–control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. Breast Cancer Res 17:22.  https://doi.org/10.1186/s13058-015-0535-x CrossRefGoogle Scholar
  5. 5.
    Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE (2009) Risk factors for triple-negative breast cancer in women under age 45. Cancer Epidemiol Biomark Prev 18:1157–1166.  https://doi.org/10.1158/1055-9965.EPI-08-1005 CrossRefGoogle Scholar
  6. 6.
    Li L, Zhong Y, Zhang H et al (2017) Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis. Mol Clin Oncol.  https://doi.org/10.3892/mco.2017.1259
  7. 7.
    Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, McDonald JA, Press MF, Bernstein L (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the Women’s Contraceptive and Reproductive Experiences Study. Cancer Res 70:575–587.  https://doi.org/10.1158/0008-5472.CAN-09-3460 CrossRefGoogle Scholar
  8. 8.
    Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103:470–477.  https://doi.org/10.1093/jnci/djr030 CrossRefGoogle Scholar
  9. 9.
    Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W, Bernstein JL (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130:587–597.  https://doi.org/10.1007/s10549-011-1616-x CrossRefGoogle Scholar
  10. 10.
    Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K (2013) Association between common risk factors and molecular subtypes in breast cancer patients. Breast 22(3):344–350CrossRefGoogle Scholar
  11. 11.
    Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11:R31.  https://doi.org/10.1186/bcr2261 CrossRefGoogle Scholar
  12. 12.
    Beaber EF, Buist DSM, Barlow WE, Malone KE, Reed SD, Li CI (2014) Recent oral contraceptive use by formulation and breast cancer risk among women 20–49 years of age. Cancer Res 74:4078–4089.  https://doi.org/10.1158/0008-5472.CAN-13-3400 CrossRefGoogle Scholar
  13. 13.
    Chen L, Li CI, Mei-Tzu CT et al (2016) Reproductive factors and risk of luminal, HER2-overexpressing and triple negative breast cancer among multiethnic women. Cancer Epidemiol Biomark Prev 25:1297–1304.  https://doi.org/10.1158/1055-9965.EPI-15-1104 CrossRefGoogle Scholar
  14. 14.
    Margolese RG, Hortobagyi GN, Buchholz TA (2003) Breast cancer biology, ed. Kufe DW, Pollock RE, Weichselbaum RR, et al. Hamilton (ON): BC Decker Holland-Frei cancer medicine (6th edition). Available from: https://www.ncbi.nlm.nih.gov/books/NBK13081/
  15. 15.
    Raun X, Neubauer H, Yang Y et al (2012) Progestogens and membrane-initiated effects on the proliferations of human breast cancer cells. Climacteric 15:467–472.  https://doi.org/10.3109/13697137.2011.648232 CrossRefGoogle Scholar
  16. 16.
    Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR, Clarke CL (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150:3318–3326.  https://doi.org/10.1210/en.2008-1630 CrossRefGoogle Scholar
  17. 17.
    Narvaiza DG, Navarrete MAH, Falzoni R, Maier CM, Nazario ACP (2008) Effect of combined oral contraceptives on breast epithelial proliferation in young women. Breast J 14(5):450–455CrossRefGoogle Scholar
  18. 18.
    Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7:791–799CrossRefGoogle Scholar
  19. 19.
    Visvader JE, Stingl J (2014) Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev 28:1143–1158.  https://doi.org/10.1101/gad.242511.114 CrossRefGoogle Scholar
  20. 20.
    Dontu G, El-Ashry D, Wicha MS (2004) Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15(5):193–197CrossRefGoogle Scholar
  21. 21.
    Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360(9328):187–195CrossRefGoogle Scholar
  22. 22.
    Gammon MD, Hibshoosh H, Terry MB et al (1999) Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomark Prev 8:413–419Google Scholar
  23. 23.
    Busund M, Bugge NS, Braaten T, Waaseth M, Rylander C, Lund E (2018) Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: the Norwegian Women and Cancer Study. Int J Cancer 142:2293–2302.  https://doi.org/10.1002/ijc.31266 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  3. 3.Department of Internal MedicineUniversity of New Mexico and the University of New Mexico Comprehensive Cancer CenterAlbuquerqueUSA

Personalised recommendations